Equities researchers at StockNews.com assumed coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the stock.
BiondVax Pharmaceuticals Price Performance
NASDAQ BVXV opened at $2.77 on Tuesday. The company has a quick ratio of 5.76, a current ratio of 5.76 and a debt-to-equity ratio of 5.92. BiondVax Pharmaceuticals has a 12-month low of $2.37 and a 12-month high of $22.90. The company has a market capitalization of $3.97 million, a PE ratio of -0.69 and a beta of 2.65. The firm’s 50 day moving average is $6.01 and its 200-day moving average is $8.55.
BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) last posted its quarterly earnings data on Wednesday, November 30th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.16. Equities research analysts anticipate that BiondVax Pharmaceuticals will post -0.3 earnings per share for the current fiscal year.
Institutional Trading of BiondVax Pharmaceuticals
BiondVax Pharmaceuticals Company Profile
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
- Get a free copy of the StockNews.com research report on BiondVax Pharmaceuticals (BVXV)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- Analysts Like The Fit Of Skechers USA
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.